Anne Cayre

<i>KRAS</i> Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

Astrid Lièvre, Jean‐Baptiste Bachet, Valérie Boige et al. · Journal of Clinical Oncology · 2008 · 1.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Analysis of <i>PTEN</i> , <i>BRAF</i> , and <i>EGFR</i> Status in Determining Benefit From Cetuximab Therapy in Wild-Type <i>KRAS</i> Metastatic Colon Cancer

Pierre Laurent‐Puig, Anne Cayre, Gilles Manceau et al. · Journal of Clinical Oncology · 2009 · 665 citations

Medicine, Oncology, Pharmacology +17

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network

Michèle Beau‐Faller, Nathalie Prim, Anne-Marie Ruppert et al. · Annals of Oncology · 2013 · 320 citations · Full text

Medicine, Genetics, Oncology +7

Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact

Jean‐Marc Nabholtz, Catherine Abrial, Marie‐Ange Mouret‐Reynier et al. · Annals of Oncology · 2014 · 122 citations

Medicine, Oncology, Pharmacology +17

Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study

Thierry André, Hélène Blons, May Mabro et al. · Annals of Oncology · 2012 · 93 citations · Full text

Medicine, Oncology, Pharmacology +11